The Impact of Interval between Recurrence and Reinjection in Anti-VEGF Therapy for Diabetic Macular Edema in Pro Re Nata Regimen. [PDF]
Takamura Y +11 more
europepmc +1 more source
Framework for Evaluation of the IT&C Audit Metrics Impact [PDF]
The paper defines an assessment system for performance of IT&C audit process. The analytical models of performance indicators are provided together with the interpretation of their results.
Marius POPA
core
Real-Life Efficacy of Bevacizumab Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion according to Pro Re Nata or Treat-and-Extend Regimen in Eyes with or without Epiretinal Membrane. [PDF]
Hamam M +5 more
europepmc +1 more source
Dysmenorrhea can be a burden on individuals and families. Investigating dysmenorrhea has become important to further our understanding of this issue and to research the measures that have been effective in managing it in other populations.
Eunice Osuala +3 more
doaj +1 more source
Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: A phase 3 randomized clinical trial. [PDF]
Yoon CK +5 more
europepmc +1 more source
Operational alternatives for LANDSAT in California [PDF]
Data integration is defined and examined as the means of promoting data sharing among the various governmental and private geobased information systems in California.
Gialdini, M. J., Wilson, P.
core +1 more source
Predictive role of optical coherence tomography angiography for exudation recurrence in patients with type 1 neovascular age-related macular degeneration treated with pro-re-nata protocol. [PDF]
Choi M, Kim SW, Yun C, Oh JH, Oh J.
europepmc +1 more source
As-Needed Prescribing and Administration of Psychotropic Medications in Assisted Living: A 7-State Study. [PDF]
Carder P +5 more
europepmc +1 more source
Background Diabetic macular edema (DME) is a leading cause of vision impairment. This study evaluated the effects of multiple anti-VEGF intravitreal injections, including a novel anti-VEGF PRO-169, on best-corrected visual acuity (BCVA) and central ...
Guillermo Salcedo-Villanueva +6 more
doaj +1 more source

